Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Gipfel Life Sciences Gmbh

Clinical trials sponsored by Gipfel Life Sciences Gmbh, explained in plain language.

Not yet recruiting 1

New Two-Pronged attack on ALS targets brain inflammation

Disease control Not yet recruiting

This study is testing whether combining two drugs, galunisertib and nerandomilast, can slow the progression of ALS in patients who have a specific biomarker called GREM2. The drugs aim to reduce harmful inflammation and scarring in the nervous system. About 60 adults with relativ…

Phase: PHASE2, PHASE3 • Sponsor: Gipfel Life Sciences GmbH • Aim: Disease control

Last updated Apr 04, 2026 05:05 UTC